DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Poziotinib is an investigational drug.
There have been 18 clinical trials for Poziotinib. The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2015.
The most common disease conditions in clinical trials are Breast Neoplasms, Lung Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are Spectrum Pharmaceuticals, Inc, Hanmi Pharmaceutical Company Limited, and National OncoVenture.
There are fifty US patents protecting this investigational drug and five hundred and two international patents.
Recent Clinical Trials for Poziotinib
|Study of Poziotinib in Japanese Patients With NSCLC||Spectrum Pharmaceuticals, Inc||Phase 1/Phase 2|
|Study of the Absorption, Metabolism, and Excretion Following a Single Dose of [14C]-Poziotinib in Healthy Male Subjects||Spectrum Pharmaceuticals, Inc||Phase 1|
|A Phase 2 Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies||Spectrum Pharmaceuticals, Inc||Phase 2|
Top disease conditions for Poziotinib
Top clinical trial sponsors for Poziotinib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Poziotinib||Get Started Free||Compounds and methods for inhibiting vacuolar ATPase||University of Southern California (Los Angeles, CA)||Get Started Free|
|Poziotinib||Get Started Free||Gene fusions and gene variants associated with cancer||LIFE TECHNOLOGIES CORPORATION (Carlsbad, CA)||Get Started Free|
|Poziotinib||Get Started Free||Controlled release dosage form||TRIASTEK, INC. (Nanjing, CN)||Get Started Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Poziotinib||Australia||AU2014254394||2033-04-17||Get Started Free|
|Poziotinib||China||CN105378110||2033-04-17||Get Started Free|
|Poziotinib||China||CN106414768||2033-04-17||Get Started Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|